Arca
Skip to content
Tools
Tools

MAPT: Microtubule-associated protein tau

Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity.

  • Drugs that act on it: 6
  • Approved: 0
  • In phases 1 to 3: 6
  • Sponsors: 6

Who is on it, and how far along

Every drug ChEMBL records acting on MAPT, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody 6

Approved0

    Phase 30

      Phase 26

      • Bepranemab
      • Gosuranemab
      • Posdinemab
      • Semorinemab
      • Tilavonemab
      • Zagotenemab

      Phase 10

        Sponsors

        Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

        • UCB Biopharma SRL117%

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Microtubule-associated protein tau inhibitor.
        BepranemabPhase 2UCB Biopharma SRLAntibodyInhibitor1
        GosuranemabPhase 2BiogenAntibodyInhibitor0
        PosdinemabPhase 2Johnson & JohnsonAntibodyInhibitor0
        SemorinemabPhase 2RocheAntibodyInhibitor0
        TilavonemabPhase 2AbbVieAntibodyInhibitor0
        ZagotenemabPhase 2Eli LillyAntibodyInhibitor0

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 1 in all, from ClinicalTrials.gov.
        TrialDrugPhaseStatusLead sponsorFirst posted
        A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear PalsyBepranemabPhase 1Active, not recruitingUCB Biopharma SRLDec 8, 2020

        Diseases most associated with it

        Open Targets association score, 0 to 1; all associations
        • Pick disease0.76
        • Supranuclear palsy, progressive, 10.74
        • Progressive supranuclear palsy-parkinsonism syndrome0.71
        • Atypical progressive supranuclear palsy syndrome0.71
        • Late-onset Parkinson disease0.64
        • Semantic dementia0.64
        • Parkinson disease0.55
        • Mental deterioration0.37

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1293224, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P10636, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.